Home » Stocks » ATXI

Avenue Therapeutics, Inc. (ATXI)

Stock Price: $3.06 USD -0.12 (-3.77%)
Updated Oct 30, 2020 12:28 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 51.11M
Revenue (ttm) n/a
Net Income (ttm) -10.79M
Shares Out 16.70M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE 17.99
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $3.06
Previous Close $3.18
Change ($) -0.12
Change (%) -3.77%
Day's Open 3.19
Day's Range 3.01 - 3.20
Day's Volume 78,486
52-Week Range 2.85 - 12.34

More Stats

Market Cap 51.11M
Enterprise Value 45.85M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 16.70M
Float 6.61M
EPS (basic) -0.66
EPS (diluted) -0.66
FCF / Share -0.62
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 137,144
Short Ratio 0.54
Short % of Float 2.08%
Beta 0.22
PE Ratio n/a
Forward PE 17.99
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 12.46
Revenue n/a
Operating Income -10.97M
Net Income -10.79M
Free Cash Flow -10.20M
Net Cash 5.26M
Net Cash / Share 0.31
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -65.30%
ROE -119.82%
ROIC 6,326.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(194.12% upside)
Current: $3.06
Target: 9.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-26.27-21.64-11.42-2.38-4.84
Net Income-25.91-21.55-12.26-3.18-5.23
Shares Outstanding15.7210.246.632.862.70
Earnings Per Share-1.65-2.10-1.85-1.11-1.93
Operating Cash Flow-26.26-18.22-6.80-1.63-0.90
Free Cash Flow-26.26-18.22-6.80-1.63-0.90
Cash & Equivalents8.752.6721.780.200.01
Total Debt---5.873.87
Net Cash / Debt8.752.6721.78-5.68-3.85
Book Value6.80-0.6319.38-8.25-5.14
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Avenue Therapeutics, Inc.
Country United States
Employees 4
CEO Lucy Lu

Stock Information

Ticker Symbol ATXI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ATXI
IPO Date June 27, 2017


Avenue Therapeutics, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.